Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Poly-l-lysine G3 + vitamin A is a combination dermocosmetic formulation that includes third-generation poly-L-lysine dendrigraft (G3) and vitamin A. Poly-L-lysine is a synthetic cationic polymer known for its biocompatibility and ability to enhance the stability, penetration, and efficacy of co-administered active ingredients. Vitamin A (retinol or its derivatives) is widely used in dermatology for its role in skin cell turnover, repair, and anti-inflammatory effects. This combination has been studied as part of a sequential skincare regimen for atopic dermatitis, where it was applied in the evening after a morning application of poly-L-lysine G2/vitamin C. The product aims to provide natural, plant-derived active ingredients suitable for sensitive or atopic skin by leveraging the synergistic properties of both components to improve hydration, barrier function, and clinical symptoms such as pruritus and inflammation[1]. Clinical studies have shown significant improvements in Dermatology Life Quality Index (DLQI) and SCORAD scores after 28 days of use[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on poly-l-lysine G3 + vitamin A.